Globally, synovial sarcoma remains a rare but aggressive malignancy with a 5-year survival rate of 70% to 80% and a 10-year ...

Google's Gemini is set to roll out a presentation creation feature, allowing users to generate presentations from documents ...

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival ...

In the months and years after East Palestine’s train derailment, researchers from five universities started studies on the environmental and health effects. Those researchers presented their ...

The influence of external proof is important — but lasting impact comes from building it inside your organization.

Perimenopausal women who used estrogen for at least 10 years before their periods stopped had 60% lower odds for breast ...

A snapshot of the CX market: aligning customer expectations with company strategies. Global and local CX leaders, strategy, ...

HAYWARD, Calif., October 10, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties. See why OMER is a Buy.

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery ...

The Healthcare Innovation Summit Africa (HISA) 2025 has an exceptional Speakers lineup for their event taking place on 22-23 October 2025 ...

“The future of growth won’t be bought, it will be built,” says Brian Lesser, chief executive officer of WPP Media. “It’s not ...